株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

慢性蕁麻疹:パイプライン製品の分析

Chronic Urticaria Or Hives - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 213077
出版日 ページ情報 英文 51 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
慢性蕁麻疹:パイプライン製品の分析 Chronic Urticaria Or Hives - Pipeline Review, H2 2017
出版日: 2017年10月10日 ページ情報: 英文 51 Pages
概要

慢性蕁麻疹は隆起した、様々な大きさの、赤色または白色の痒みのあるみみず腫れ(膨疹)が現れたり消えたりする症状を指します。たいていの場合、蕁麻疹は1週間以内に治まりますが、中には長期的に症状が続く人々もいます。6週間以上継続している蕁麻疹や、一旦は消失したものの頻繁に再発する蕁麻疹を慢性蕁麻疹と言います。

当レポートでは、世界各国での慢性蕁麻疹治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

慢性蕁麻疹の概要

治療薬の開発

  • パイプライン製品の概要

慢性蕁麻疹:企業で開発中の治療薬

慢性蕁麻疹:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

慢性蕁麻疹:企業で開発中の製品

慢性蕁麻疹の治療薬開発に従事している企業

  • AstraZeneca Plc
  • Biofrontera AG
  • ELORAC, Inc.
  • Faes Farma, SA
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • J Uriach Y Compania, S.A.
  • Mabtech Limited
  • Merck & Co., Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Panacea Biotec Limited

慢性蕁麻疹:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

慢性蕁麻疹:最近のパイプライン動向

慢性蕁麻疹:休止中のプロジェクト

慢性蕁麻疹:開発が中止された製品

慢性蕁麻疹:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9787IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2017, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 4, 4 and 3 respectively.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Urticaria Or Hives - Overview
    • Chronic Urticaria Or Hives - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Chronic Urticaria Or Hives - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
    • Biofrontera AG
    • ELORAC Inc
    • Faes Farma SA
    • Fountain Biopharma Inc
    • Genentech Inc
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd
    • Mycenax Biotech Inc
    • Novartis AG
    • Synermore Biologics Co Ltd
  • Chronic Urticaria Or Hives - Drug Profiles
    • BF-Derm-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bilastine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cetirizine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cidoxepin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GDC-0853 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2646264 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ligelizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chronic Urticaria Or Hives - Dormant Projects
  • Chronic Urticaria Or Hives - Discontinued Products
  • Chronic Urticaria Or Hives - Product Development Milestones
    • Featured News & Press Releases
      • Dec 19, 2016: Aralez Announces Commercial Launch Of BLEXTEN In Canada
      • Nov 18, 2016: Taiho and Meiji Announce the Launch of Bilanoa Tablets 20 mg, an Oral Anti-allergy Drug in Japan
      • Sep 28, 2016: Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa Tablets, an Oral Anti-allergy Drug in Japan
      • Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN
      • Nov 13, 2015: Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
      • May 25, 2015: Bilastine in Japan: Phase III trials completed and ready for registration
      • Jul 02, 2012: Faes Farma Receives Approval For Bilastine In Mexico
      • Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil
      • Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain
      • Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries
      • Dec 02, 2010: Faes Farma: Bilastine is approved in eight european countries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Urticaria Or Hives, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Chronic Urticaria Or Hives - Pipeline by Biofrontera AG, H2 2017
  • Chronic Urticaria Or Hives - Pipeline by ELORAC Inc, H2 2017
  • Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, H2 2017
  • Chronic Urticaria Or Hives - Pipeline by Fountain Biopharma Inc, H2 2017
  • Chronic Urticaria Or Hives - Pipeline by Genentech Inc, H2 2017
  • Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
  • Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, H2 2017
  • Chronic Urticaria Or Hives - Pipeline by Novartis AG, H2 2017
  • Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, H2 2017
  • Chronic Urticaria Or Hives - Dormant Projects, H2 2017
  • Chronic Urticaria Or Hives - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Chronic Urticaria Or Hives, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top